Valneva Se · EURONEXT:VLA
Valneva — Merger or Acquisition (August 2024)
10 slides from Valneva's merger presentation, Aug 1, 2024
Slide 1: Valneva and LimmaTech Enter into a Strategic Partnership on Shigella Vaccine S4V
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate (“S4V”) August 01, 2024
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful . Valneva is a European company . Information
Slide 3: Aligned with Our Vision, Mission and Corporate Strategy
1 Low - and middle - income countries Opportunity to develop first - in - class vaccine for a life - threatening disease Expected to provide near - term R&D upside for investors with appealing risk - benefit profile 3 Aligned with Our Vision ▪ Addresses significant unmet medical need; Shigellosis is
Slide 4: Strategic Partnership with LimmaTech Biologics (LMTB)
Strategic Partnership with LimmaTech Biologics (“LMTB”) Valneva / LimmaTech - Shigella Partnership 4 1 https://lmtbio.com/wp - content/uploads/2024/02/20240221_LimmaTech_Shigella - Interim - Data - PR_Final.pdf Valneva gains exclusive worldwide rights to world’s most clinically advanced tetravalent
Slide 5: Shigellosis: Significant Unmet Medical Need
Shigellosis: Significant Unmet Medical Need 1 No approved Shigella vaccine is currently available Valneva / LimmaTech - Shigella Partnership 5 ▪ Second - leading cause of fatal diarrheal disease worldwide ▪ Estimated to cause up to 165 million cases and 600,000 deaths each year, particularly among c
Slide 6: Potential first-in-class vaccine, estimated >$500 million global market
Potential first - in class vaccine, estimated >$500 million global market 1 Committed to providing equitable access to novel vaccines² Product ▪ 4 - valent Shigella bio - conjugate vaccine ( S. flexneri 2a, 3a, 6 and S. sonnei O - antigens) Indication ▪ Prevention of Shigellosis caused by vacci ne s
Slide 7: Risk-mitigating and staggered development plan
Risk - mitigating and staggered development plan Risk - mitigated clinical strategy allows for efficient capital allocation in line with mid - term guidance 1 Accountable for conduct and payment; 2. Controlled human infection model Valneva / LimmaTech - Shigella Partnership 7 Anticipated read - out
Slide 8: Strategic Partnership with LMTB on Shigella candidate S4V: Key terms
Strategic Partnership with LMTB on Shigella candidate S4V Key terms ▪ VLA receives global exclusive license to develop, manufacture and commercialize “S4V ” (4 valent (flexneri 2a, 3a, 6 and sonnei O - antigens) bio - conjugate vaccine for the prevention of a disease caused by Shigella) ▪ LMTB to re
Slide 9: Valneva's Commercial and R&D Portfolio
Commercial Phase 3 Phase 2 Phase 1 Pre - Clinical Vaccine Design Program IXIARO ® Commercial Products DUKORAL ® IXCHIQ ® VLA15: Lyme disease Clinical Programs VLA1553: Chikungunya S4V: Shigellosis VLA1601: Zika VLA2112: EBV Key Pre - Clinical Activities Various Enteric diseases Valneva’s Commercial
Slide 10: Thank you
Thank you ~~ Merci Of Danke ‘e Tack valneva